TrialLupus science & medicine2025

Pharmacokinetics, effectiveness, tolerability and effect on quality of life of open-label tofacitinib for the treatment of moderately active mucocutaneous manifestations of SLE: results of a 76-week phase II study.

Ivanna Romankevych et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.